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ABSTRACT. Background: It is uncertain whether homocys-
teine and the metabolic syndrome or its components are re-
lated in the general population, as studies investigating the
association between homocysteine levels and insulin resis-
tance have shown conflicting results. Methods: In an ancil-
lary study to the Persian Gulf Healthy Heart Study, a cohort
study of Iranian men and women aged ≥25 yr, a random sam-
ple of 1754 subjects were evaluated for the association of
plasma homocysteine levels and the metabolic syndrome us-
ing National Cholesterol Education Program (NCEP)-Adult
Treatment Panel (ATP)-III criteria. Total homocysteine levels
and high sensitivity C-reactive protein (CRP) were determined
by enzyme-linked immunosorbent assays. Results: Subjects
with lower HDL-cholesterol and higher blood pressure
showed significantly higher homocysteine levels (p=0.001
and p<0.0001; respectively). There was no significant differ-
ence in serum levels of homocysteine between subjects with
and without the metabolic syndrome. In multiple logistic re-
gression analysis, the metabolic syndrome did not show a
significant association with serum homocysteine levels after
adjusting for sex, age, smoking, fruit and vegetable intake
pattern, body mass index, and physical inactivity. Concurrent
elevated CRP levels and the metabolic syndrome also did not
show a significant association with serum homocysteine lev-
els after adjusting for sex, age, and lifestyle cardiovascular
risk factors. Conclusions: There was no association between
the metabolic syndrome using NCEP-ATPIII criteria and ho-
mocysteinemia in this study. These data refute the hypothe-
sis that homocysteine levels are influenced by the metabol-
ic syndrome, at least in general healthy population.
(J. Endocrinol. Invest. 32: 406-410, 2009)
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INTRODUCTION
Elevated levels of serum total homocysteine are toxic to
vascular endothelium, including endothelial dysfunction
and contributing to development of atherosclerosis in-
dependent of standard cardiovascular disease (CVD) risk
factors in diabetic and non-diabetic subjects (1).
Several observations suggest that there might be links
between insulin resistance (IR) and hyperhomocysteine-
mia (2, 3). Hyperhomocysteinemia may be a cause and/or
a consequence of IR. In an insulin resistant state, elevat-
ed homocysteine plasma levels may be the result of hy-
perinsulinemia, as observed in animal models (4, 5). At
the same time, homocysteine may lead to IR through in-
hibition of insulin-receptor kinase activity in vitro (6, 7).
Plasma levels of insulin seem to influence homocysteine
metabolism, possibly through effects on glomerular fil-
tration or by influencing activity of key enzymes in ho-
mocysteine metabolism, including 5, 10-methylenete-
trahydrofolate reductase or cystathione B-synthase (2).
There is, however, conflicting evidence about whether
there is a general relationship between IR and homocys-
teine levels in healthy humans (8-10).
The common clustering of glucose intolerance, abdominal
adiposity, hypertriglyceridemia, low HDL-cholesterol (HDL-
C) level and high blood pressure in a single individual is re-
ferred to as the metabolic syndrome (11, 12). The metabol-
ic syndrome is expected to be diagnosed in millions of sub-
jects in the near future worldwide by both World Health
Organization (WHO) and National Cholesterol Education
Program (NCEP)-Adult Treatment Panel (ATP)-III (NCEP-
ATP III) criteria. The prevalence of metabolic syndrome has
been reported to be 24% in the US adult population (12).
IR is considered to be the major underlying pathophysi-
ological feature of the metabolic syndrome, as it inter-
feres in many metabolic pathways (13).
Although hyperhomocysteinemia and the metabolic syn-
drome are both associated with CVD, the association be-
tween fasting homocysteine levels and metabolic syndrome
is not well characterized and studies investigating the as-
sociation between the metabolic syndrome and homocys-
teine levels have shown conflicting results (2, 3, 14-16). A
very few population-based studies reported the associa-
tion of metabolic syndrome and hyperhomocysteinemia
(14-16). Of these, one in Mexican American men failed to
show an association between homocysteinemia and dia-
betes status or fasting serum insulin (15), whereas the oth-
er, from the Framingham Offspring Study, did show a mod-
erate association between components of the metabolic
syndrome and homocysteine levels (2). There is limited da-
ta about the relationship between hyperhomocysteinemia
and the metabolic syndrome in Asian countries (16). The
main objective of this study is to investigate the associa-
tion of metabolic disease and its major components with
homocysteine using NCEP-ATP III criteria.
MATERIALS AND METHODS
The Persian Gulf Healthy Heart Study is set up to determine the
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risk factors for CVD among the Northern Persian Gulf popula-
tion (Bushehr and Hormozghan Provinces) and to develop com-
munity-based interventional projects to change the lifestyles of
the population. The design of this study encompasses two ma-
jor components: phase I is a cross-sectional prevalence study of
unhealthy lifestyle and ischemic heart disease (IHD) and associ-
ated risk factors, and phase II is a multiple interventional pro-
ject for reduction of CVD in the region.
Community sampling and baseline examinations
In phase I of the study, a multiple-stage stratified cluster random
sampling technique was used to select 3000 people aged ≥25 yr
from major ports of Bushehr Province (an Iranian province with the
greatest border with the Persian Gulf). The studied ports of the
Northern Persian Gulf were Bushehr Port (the center of Bushehr
Province, with a population of 150,000 and coronary events of
481.05 and 156.61 per 100,000 for men and women, respective-
ly), Genaveh and Deilam Ports. Examinations were conducted in
2003-04. All subjects were asked to fast and to arrive at the survey
center between 7:30-9:30 h. Blood pressure was assessed twice
on the right arm after a 15-min rest in the sitting position, using a
standard mercury sphygmomanometer. Height and weight were
measured using a stadiometer. Heavy outer garments and shoes
were removed before measuring height and weight. Body mass
index (BMI) was calculated. Waist circumference was defined at
the midway level between the costal margins and the iliac crests.
Hip circumference was measured at the level of the greater
trochanters. A resting 12-lead electrocardiogram was performed. 
A fasting blood sample was taken, all samples were promptly cen-
trifuged, separated and analyses were carried out at the Persian
Gulf Health Research Center on the day of blood collection using
a Selectra 2 autoanalyzer (Vital Scientific, Spankeren, The Nether-
lands). Glucose was assayed by enzymatic (glucose oxidase) col-
orimetric method using a commercial kit (Pars Azmun Inc; Tehran,
Iran). Serum total cholesterol and HDL-C were measured using a
cholesterol oxidase phenol aminoantipyrine and triglycerides using
a glycerol-3 phosphate oxidase phenol aminoantipyrine enzymat-
ic method. Serum LDL-cholesterol was calculated using the Fried-
wald formula; LDL-cholesterol was not calculated when triglyceride
concentration was >400 mg/dl.
The metabolic syndrome was diagnosed with the criteria in-
dicated by the NCEP-ATP III (17). According to these criteria,
subjects with the metabolic syndrome are those with any com-
bination of three or more of the following risk determinants:
fasting plasma glucose ≥6.1 mmol/l, blood pressure ≥130/≥85
mmHg or antihypertensive treatment, plasma triglycerides
≥1.7 mmol/l, plasma HDL-C<1.03 mmol/l in men and <1.29
mmol/l in women, and waist circumference >102 cm in men or
>88 cm in women. 
EKGs were coded on the basis of the Minnesota coding criteria
(18). Codes 1.1, 1.2, 1.3, 4.1-4.4, 5.1-5.3, and 7.1 were classified
as electrocardiographic-defined coronary artery disease (CAD). 
Serology
Sera were screened for IgG antibodies against Helicobacter pylori
with an enzyme-linked immunosorbent assay (ELISA) (RADIM SpA,
Italia), and the samples were considered positive with IgG values
higher than 30 RU/ml. An enzyme immunoassay for the determi-
nation of total homocysteine in blood was used; the quantifica-
tion limit of the DRG Homocysteine EIA (DRG International, Inc.
USA) was 1.0 μmol/l with a coefficient of variation (CV) <20%. Sera
were separated shortly after collection, to avoid artifactual in-
creases. The interference with the DRG Homocysteine was <10%
for bilirubin, hemoglobin, lipids, protein and red blood cells. Mea-
surement of CRP by a high-sensitivity CRP (hs-CRP) assay was car-
ried out. The minimum detectable concentration of the CRP HS
ELISA (DRG International, Inc. USA) assay was estimated to be 0.1
mg/l. Additionally, the functional sensitivity was determined to
be 0.1 mg/l (as determined with inter-assay % CV <20%). 
Statistical methods
The significance of the difference in the results of the two groups
was determined by chi-square analysis using 2×2 contingency ta-
bles. A two-tailed t-test was used to compare the mean values
across groups. p<0.05 was considered statistically significant.
We found that log transformation of CRP gave a better fit to a
Gaussian distribution. The geometric mean for CRP was defined
as the arithmetic mean of the log-transformed data ±2 SD, raised
to the power of 10. 
Multiple logistic regression analysis was used to ascertain the
associations between the metabolic syndrome and homocys-
teinemia. Sex, age, smoking, fruit, and vegetable intake pattern,
BMI and physical inactivity were considered as covariates, and
the metabolic syndrome also as the dependent variable. p<0.05
was considered statistically significant. Statistical analysis was
performed with an IBM computer using the SPSS 9.05 statistical
software package (SPSS Inc., Chicago, IL).
RESULTS
A total of 1754 (49.2% males, 50.8% females) of the stud-
ied population were evaluated for associations of the
metabolic syndrome and serum levels of homocysteine.
Of the studied subjects, 36.1% was between 25-34 yr,
29.0% between 35-44 yr, 21.9% between 45-54 yr, and
12.7% between 55-66 yr. 
The prevalence of consumption of antihypertensive, hy-
polipidemic and anti-diabetic drugs were 6.5%, 3.5% and
3.8%, respectively. 
A total of 52.1% of the subjects (56.30% of males and
48.0% of females; p<0.0001) had the metabolic syn-
drome (NCEP-ATP III criteria). 
Clinical characteristics, laboratory values and homocys-
teine levels in males and females are presented in Table 1.
The mean of homocysteine was 14.71 (7.09) μmol/l in the
studied population. Quartiles (Q) for the population dis-
tribution for homocysteine were as follows: Q1, 0.1-10.2
μmol/l; Q2, 10.3-14.30 μmol/l; Q3, 14.31-18.80 μmol/l;
and Q4, 18.81-46.70 μmol/l. The mean levels of homo-
cysteine were higher in men (16.85, SD=7.33 μmol/l) than
women (12.67, SD=6.19 μmol/l), (p<0.0001). 
There was no significant difference in serum levels of ho-
mocysteine between subjects with and without the
metabolic syndrome [17.09 (6.85 SD) vs 16.55 (7.89)
μmol/l for men and 12.91 (6.25) vs 12.45 (6.14) μmol/l for
women, respectively (p>0.05)]. 
Mean homocysteine levels did not differ significantly in sub-
jects with and without impaired fasting glucose [15.26 (8.64)
μmol/l and 14.81 (6.99) μmol/l, respectively (p>0.05)].
Mean homocysteine levels were compared between two
groups divided by each component of metabolic syn-
drome (Table 2). Subjects with lower HDL-C and higher
blood pressure showed significantly higher homocysteine
levels (p=0.001 and p<0.0001; respectively). 
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Table 3 shows age-adjusted odds ratios (OR) [95% con-
fidence interval (CI)] between metabolic syndrome, and
lifestyle cardiovascular risk factors, and serum homocys-
teine levels. In multiple logistic regression analysis, the
metabolic syndrome did not show a significant associa-
tion with serum homocysteine levels in males [OR=1.00,
CI (0.98-1.02); p=0.47] and females [OR=1.00, CI (0.97-
1.02); p=0.84] after adjusting for age, smoking, fruit and
vegetable intake pattern, BMI, and physical inactivity.
Concurrent elevated CRP levels (defined as more than
3.0 mg/l) and the metabolic syndrome (concurrent ele-
vated CRP and the metabolic syndrome) also did not
show a significant association with serum homocysteine
levels in males [OR=1.01, CI (0.98-1.04); p=0.39] and fe-
males [OR=0.99 CI (0.96-1.02); p=0.70] adjusting for age
and lifestyle cardiovascular risk factors.
The metabolic syndrome, in subjects with non-fatal IHD
by electrocardiogram criteria was not associated with el-
evated levels of homocysteine compared to subjects with-
out concurrent metabolic syndrome and non-fatal IHD
[14.74 (7.12) μmol/l vs 14.40 (6.66) μmol/l, respectively].
DISCUSSION
In this study, there was no association between the
metabolic syndrome using NCEP-ATP III criteria and ho-
mocysteinemia. Homocysteine values according to the
presence or absence of abdominal obesity, hypertriglyc-
eridemia, hypertension, and fasting hyperglycemia
showed no significant differences. On the other hand,
serum homocysteine levels were significantly higher in
subjects with low HDL-C and higher blood pressure, two
metabolic syndrome criteria.
The studies on the relationship between homocysteine lev-
els and metabolic syndrome or IR show conflicting results
(2, 3, 14-16). Most studies have been based on small pop-
ulation samples or have been restricted to diabetic pa-
tients. To our knowledge, only 5 other large-scale epi-
demiological studies exist to date (2, 3, 14-16). Of these,
3 studies have investigated the relationships between ho-
mocysteinemia, serum insulin, and features of IR syndrome
(2, 3, 15). Meigs et al. assessed the relationship between
hyperinsulinemia, phenotypes of IR syndrome, and levels
of fasting homocysteine in the population-based Fram-
ingham Offspring Study (2). They found positive associa-
tions between fasting levels of plasma homocysteine and
some individual traits associated with IR (2). 
In contrast, in a national sample of Mexican American
men aged 40-74 yr, serum homocysteine was not asso-
ciated with prevalent diabetes mellitus, body fat distri-
bution, obesity or other variables of the IR syndrome (15).
In a recent work by Bjorck et al., a significant association
between homocysteine and both serum insulin and home-
ostasis model assessment (HOMA) of IR were found in a
population-based sample of Swedish men and women (3). 
These studies investigated the relationship between ho-
mocysteine levels and IR, thus linking homocysteine and
the metabolic syndrome indirectly. However, NCEP-ATP
III criteria for definition of metabolic syndrome were on-
ly used in two large recent studies (14-16). In 722 partic-
ipants undergoing medical checkups in a university hos-
pital in Korea, homocysteine levels failed to show statis-
tically significant association with metabolic syndrome
defined by either the modified NCEP-ATP III or newly
recommended International Diabetes Federation criteria
(16). Garcin et al. used NCEP-ATP III criteria of the
metabolic syndrome in a French male population (14).
Mean homocysteinemia was 10.96 (5.01) μmol/l for the
whole population and did not differ significantly with
[11.4 (6.0) μmol/l] or without [10.9 (5.0) μmol/l] the
metabolic syndrome, as dose value distribution. Plasma
homocysteine level did not correlate with the metabolic
syndrome criteria (14).
The present study indicates that homocysteine levels were
independent of the metabolic syndrome using NCEP-ATP
Men Women p
(no.=864) (no.=890)
Waist (cm) 94.4 (11.5) 98.2 (14.1) <0.0001
BMI (kg/m2) 26.0 (4.6) 28.3 (5.6) <0.0001
Systolic blood pressure (mmHg) 130.9 (47.4) 121.4 (23.5) <0.0001
Diastolic blood pressure (mmHg) 83.7 (47.5) 77.2 (189.2) <0.0001
Total Cholesterol (mg/dl) 201.6 (46.4) 210.2 (48.7) <0.0001
HDL-cholesterol (mg/dl) 41.4 (31.3) 48.0 (42.2) <0.0001
LDL-cholesterol (mg/dl) 123.9 (49.5) 130.0 (58.0) 0.01
Triglyceride (mg/dl) 181.0 (108.8) 160.8 (95.2) <0.0001
Fasting blood sugar (mg/dl) 91.2 (36.0) 93.2 (44.1) ns
C-reactive protein (mg/l)* 1.62 (3.16) 3.98 (4.07) <0.0001
Homocysteine (μmol/l) 16.85 (7.33) 12.67 (6.19) <0.0001
Ischemic heart disease (%) 8.0 14.6 <0.0001
Myocardial infarction (%) 1.6 1.0 ns
Metabolic syndrome (%) 56.3 48.0 <0.0001
Low fruit and vegetable intake (%) 92.2 90.4 ns
Physical inactivity (%) 68.5 73.1 0.01
Smoking (%) 36.5 21.9 <0.0001
Values are mean (SD), except for smoking, physical inactivity, metabolic
syndrome, ischemic heart disease, myocardial infarction, low fruit and veg-




≥102 for men/≥88 for women 1479 14.62±7.06 0.128
<102 for men/<88 for women 181 15.51±7.31
Triglyceride (mg/dl)
≥150 808 15.05±6.93 0.060
<150 852 14.40±0.22
HDL-cholesterol (mg/dl)
<40 for men/<50 for women 1048 15.18±6.97 0.001
≥40 for men/≥50 for women 612 13.92±7.21
Blood pressure (mmHg)
≥130/85 664 15.62±7.08 <0.0001
<130/85 996 14.11±7.03
Fasting glucose (mg/dl)
≥110 183 13.85±7.82 0.079
<110 1477 14.82±6.99
Table 1 - Clinical characteristics and laboratory values of a random
population of the northern Persian Gulf (the study population).
Table 2 - The differences in homocysteine values according to
the presence or absence of metabolic syndrome components
in a random population of the northern Persian Gulf.
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III criteria. This is in accordance with the findings of those
studies (the Korean and French studies) that used the
same criteria for the metabolic syndrome (14, 16). 
The strength of our study is its community-based epidemi-
ological setting. Participants of the Korean study were from
the medical checkup program (16). The population sample
of this study is the largest one in the Asian countries and
comprises males and females from a general population,
while the French study was on a male population only (14).
Among the various diagnostic criteria published up to date,
the NCEP-ATP III definition is overwhelmingly the most
common definition used in research studies, although nu-
merous limitations have been proposed in multiple stud-
ies (16). Current general conceptual frameworks include 1)
viewing the metabolic syndrome epidemic as being at-
tributable to environmental causes (e.g., the basic approach
of NCEP ATP III), 2) viewing the syndrome as primarily the
result of IR (e.g., the WHO approach), and 3) viewing in-
flammation as the underlying cause of the syndrome (19).
Given the consistency of prognostic data for hsCRP and
the practicality of its use in outpatient clinical settings, some
believe the time has come for a careful consideration of
adding hsCRP as a clinical criterion for metabolic syndrome
and for creation of an hsCRP-modified coronary risk score
useful for global risk prediction in both men and women
(20). However, by adding elevated hsCRP levels to the def-
inition of metabolic syndrome (concurrent elevated CRP
and the metabolic syndrome), we did not find a difference
in homocysteine levels between subjects with concurrent
elevated CRP and the metabolic syndrome and without el-
evated hsCRP levels.
In the French study (14), plasma homocysteine level did
not correlate with the metabolic syndrome main criteria
but, in the Korean study (16), subjects with larger waist
circumference and higher fasting blood glucose levels
showed significantly higher homocysteine levels. We
found that subjects with low HDL-C, as a main criterion of
the metabolic syndrome, had higher levels of homocys-
teine. It has been reported that homocysteine is inversely
correlated with plasma HDL-C and apolipoprotein (Apo)
A-I in patients with coronary heart disease (21). Liao et
al. confirmed this negative correlation in mice with tar-
geted deletions of the genes for apoE and cystathionine
beta-synthase (CBS) (22). Severe (plasma homocysteine
210 μmol/l) accelerates spontaneous arthrosclerosis in
the CBS(–/–)/apoE(–/–) mice, reduces the concentration
of circulating HDL, apoA-I, and large HDL particles, in-
hibits HDL function, and enhances HDL-C clearance.
Findings indicate that hyperhomocysteinemia inhibits re-
verse cholesterol transport by reducing circulating HDL
via inhibiting apoA-I protein synthesis and enhancing
HDL-C clearance. These studies suggest that homocys-
teine-induced HDL-C and apoA-I inhibition represents a
novel mechanism by which homocysteine induces
atherosclerotic CVD (22). 
Lack of information on vitamin status is one limitation in
the previous studies which assessed a link with homo-
cysteine and the metabolic syndrome. A high intake of
folate and vitamin B6 and B12 is known to correlate with
low homocysteine levels (23). Meat, fish and dairy prod-
ucts are all good sources of methionine, and vegetables
containing folic acid, beta-carotene, and vitamin C ef-
fectively lowered homocysteine levels (16). We used a 6-
item food frequency questionnaire of Behavioral Risk Fac-
tor Surveillance System (BRFSS), Centre for Desease Con-
trol USA (CDC/USA) (24) to assess the recommendation
of consuming fruits and vegetables 5 or more times per
day in the present study. A previous research has shown
that the magnitude of the correspondence between BRF-
SS estimates and reference methods of dietary intake
does not vary consistently by age, gender, or education
(25). We adjusted fruit and vegetable consumption in lo-
gistic regression model to assess the association of the
metabolic syndrome and homocysteine levels.
We acknowledge study limitations. In the present study
we used NCEP-ATP III definition for the metabolic syn-
drome. Although this definition is most often used, other
definitions for the metabolic syndrome do exist. Another
limitation of our study includes the lack of measurement
of IR from fasting glucose and insulin concentrations using
the HOMA method. Future research should include lon-
gitudinal studies of IR syndrome and serum homocysteine,
and vitamin levels to determine temporal sequence of any
relationship. Euglycemic clamp, minimal model or other
techniques for accurate measurement of IR and specific
insulin assays should be used to confirm whether IR, fast-
ing specific insulin and proinsulin vary in their association
with serum homocysteine. 
In conclusion, the present study failed to show any signifi-
cant association between homocysteine levels and metabol-
ic syndrome defined by NCEP-ATP III criteria in a general
Iranian population. These data refute the hypothesis that
homocysteine levels are influenced by the metabolic syn-
drome, at least in general healthy population.
Whereas the cross-sectional nature of our analysis pre-
cludes assigning cause or effect to the metabolic syn-
drome or hyperhomocysteinemia, the phase II of the Per-
sian Gulf Healthy Heart Study is ongoing in an Iranian
population with a high prevalence of the metabolic syn-
drome, predicting Type 2 diabetes and cardiovascular
Men Women
OR 95% CI p OR 95% CI p
Homocysteine 1.00 0.98-1.02 0.47 1.00 0.97-1.02 0.84
Smoking 1.3 9 0.99-1.95 0.05 1.42 0.98-2.06 0.06
Physical inactivity 0.63 0.45-0.88 0.08 1.16 0.83-1.61 0.37
Low fruit and vegetable intake 1.27 0.70-2.31 0.41 0.84 0.50-1.39 0.49
Body Mass Index 1.23 1.17-1.28 <0.0001 1.11 1.07-1.14 <0.0001
Table 3 - Age-adjusted odds ratios (OR) and 95% confidence intervals (CI) relating the metabolic syndrome as dependent variable,
homocysteinemia and associated risk factors as independent parameters in the Northern Persian Gulf adults.
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events. The result of this large prospective study will bet-
ter clarify any cause-effect relation of hyperhomocys-
teinemia with the metabolic syndrome. 
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